|
Champix (varenicline)
|
|
Brolucizumab (VSIQQ)
|
|
CellCept (mycophenolate mofetil): information about risks to the unborn baby
|
|
Jadenu film-coated tablets (deferasirox): new formulation, new posology, and new method of administration
|
|
Actemra® (tocilizumab) - Notification of Temporary Supply Shortage for solution for infusion (IV) & recommendations to manage potential risk of disease flare in patients
|
|
Metamizole: Risk of drug-induced liver injury
|
|
Myfortic (mycophenolic acid): risk of teratogenicity
|
|
Actemra
|
|
Tivicay (dolutegravir): updated information on neural tube defects reported in Tsepamo Study, Botswana
|
|
Tecentriq (atezolizumab), identified risk of severe cutaneous adverse reactions (SCARs) direct healthcare professional communication (DHPC)
|
